|
KMID : 0368820220610030224
|
|
Journal of the Korean Neuropsychiatr Association
2022 Volume.61 No. 3 p.224 ~ p.236
|
|
|
Korean Medication Algorithm Project for Bipolar Disorder 2022: Children and Adolescents
|
|
Yang Chan-Mo
Bahk Won-Myong
Woo Young-Sup
Jeong Jong-Hyun
Seo Jeong-Seok
Choo Il-Han
Kim Won
Lee Jung-Goo
Jung Myung-Hun
Jon Duk-In
Park Sung-Yong
Sohn In-Ki
Kim Moon-Doo
Yoon Bo-Hyun
Shim Se-Hoon
|
|
|
Abstract
|
|
|
Objectives : The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents.
Methods : We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey.
Results : The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsychotics (AAP). The first-line medications selected for these children were aripiprazole (treatme f choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic episodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, andmonotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were selected as first-line medications for these adolescents. First-line pharmacotherapeutic strategiesfor depressive episodes in adolescents were a combination of MS and an AAP, monotherapywith MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for thedepressive episodes in adolescents at high risk for bipolar disorder were a combination of MSand AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, andrisperidone were selected as first-line medications for the treatment of depressive episodes inadolescents with bipolar disorder.
Conclusion : It is expected that the present KMAP-BP 2022: children and adolescents will givethe direction and be usefully applied by clinicians to treat children and adolescents with bipolardisorders.
|
|
|
KEYWORD
|
|
|
Bipolar disorder, Children and adolescents, Pharmacotherapy, KMAP-BP 2022
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|